8 stocks surged over 50% in each of the last 3 fiscal years;...
04 Apr 2026
Sanofi India Limited has issued comprehensive communication regarding Tax Deduction at Source (TDS) provisions for its final dividend of Rs. 48 per equity share for the financial year ended December 31, 2025. The communication, dated April 2, 2026, provides detailed guidelines for shareholders on TDS compliance and dividend payment procedures.
Final Dividend and Key Dates
The Board of Directors recommended the final dividend at their meeting held on February 25, 2026, subject to approval at the 70th Annual General Meeting scheduled for April 29, 2026. The company has established important dates for dividend eligibility and compliance:
Particulars: Details Final Dividend Rate: Rs. 48 per equity share of Rs. 10 each Record Date: April 22, 2026 AGM Date: April 29, 2026 at 3:30 pm IST TDS Declaration Deadline: April 15, 2026, 5:00 pm IST Dividend Payment: On or before May 28, 2026
TDS Provisions for Resident Shareholders
The company has outlined specific TDS requirements based on shareholder categories. For resident individual shareholders, no TDS will be deducted if the aggregate dividend during the tax year does not exceed Rs. 10,000 under section 393(1)(4) of the Income Tax Act, 2025.
Where valid PAN is available for resident individual shareholders, TDS will be deducted at 10% on dividend amounts. However, shareholders providing duly signed Form 121 in accordance with section 393(6) provisions may be eligible for no TDS deduction if eligibility conditions are met.
Non-Resident Shareholder Requirements
Non-resident shareholders face TDS deduction at 20% plus applicable surcharge and cess on dividend amounts. However, they may benefit from Double Tax Avoidance Treaty (DTAA) provisions if more favorable rates apply.
To avail DTAA benefits, non-resident shareholders must submit specific documentation:
Required Documents: Details PAN Copy: Self-attested copy if allotted by Indian authorities Tax Residency Certificate: Issued by competent authority of residence country Form 41: Duly certified and electronically filed Self-Declaration: Confirming tax residency and beneficial ownership
Electronic Payment Mode and Compliance
Following SEBI regulations effective from November 19, 2025, dividend payments will be made exclusively through electronic modes including NEFT, RTGS, NECS, or other RBI-approved facilities. Physical dividend warrants and cheques have been discontinued.
Shareholders holding physical shares without updated PAN, nomination details, contact information, mobile numbers, bank account details, and specimen signatures will receive dividend payments only through electronic mode upon furnishing complete details to the company's Registrar and Transfer Agent, MUFG Intime India Private Limited.
Documentation and Submission Process
All shareholders must ensure their details are updated through their depository participant or with the RTA before the record date. The company requires residential status, valid PAN, shareholder category, email address, and complete residential address with postal code.
Document submissions must be made through the designated web portal at https://web.in.mpms.mufg.com/formsreg/submission-of-form-15g-15h.html by April 15, 2026, 5:00 pm IST. No communications regarding tax determination will be entertained after this deadline.
The company emphasizes that shareholders may file income tax returns and claim appropriate refunds if tax is deducted at higher rates due to insufficient documentation. All shareholders are advised to consult tax professionals for matters related to their specific tax situations.
Source: Company/INE058A01010/939e3a53-98a2-4e7c-a4b9-429a9825f0ee.pdf
Sanofi India Limited has filed its Business Responsibility and Sustainability Report (BRSR) for the financial year ended December 31, 2025, with stock exchanges BSE Limited and the National Stock Exchange of India Limited. The report, submitted on April 2, 2026, forms part of the company's Integrated Annual Report and demonstrates its commitment to environmental, social, and governance (ESG) principles.
Financial and Operational Overview
The pharmaceutical company reported strong financial metrics for FY25, with key parameters highlighting its market position and operational scale.
Parameter: Details Paid-up Capital: ₹230 million Turnover: ₹18,374 million Net Worth: ₹7,492 million Export Contribution: 13.31% of total turnover Market Reach: 27 States & 5 Union Territories (domestic), 25 countries (international)
The company operates with a workforce of 1,104 employees and workers across its operations, including 871 permanent employees and 226 permanent workers. The organization maintains facilities in Mumbai and Goa, with manufacturing operations focused on drugs and pharmaceuticals contributing 100% of turnover.
Environmental Performance and Climate Action
Sanofi India has achieved significant progress in its environmental commitments, particularly in greenhouse gas emissions reduction and renewable energy adoption. The company has established ambitious targets aligned with global climate goals.
Environmental Metric: Achievement/Target GHG Emissions Reduction (Scope 1 & 2): 70% reduction vs. 2019 baseline Renewable Electricity: 74% of total procurement Scope 3 Emissions: 14% reduction vs. 2019 baseline Target: Net Zero by 2045: 90% GHG reduction across operations Renewable Energy Target: 100% by 2030
The company has implemented several environmental initiatives including zero liquid discharge systems, effluent treatment plants, and HFO-based chillers expected to reduce carbon footprint by approximately 1,500 tons annually. Water stewardship plans have been implemented across sites, with treated wastewater being repurposed for gardening and other non-potable uses.
Employee Welfare and Human Resources
The sustainability report highlights comprehensive employee welfare measures and diversity initiatives across the organization.
Workforce Demographics and Benefits
Category: Total Male Female Permanent Employees: 871 733 (84%) 138 (16%) Permanent Workers: 226 220 (97%) 6 (3%) Health Insurance Coverage: 100% 100% 100% Accident Insurance: 100% 100% 100%
The company provides comprehensive benefits including health insurance, accident coverage, maternity and paternity benefits, and day care facilities. Training programs covered 100% of board members, key management personnel, and employees, focusing on areas such as ethics, safety, human rights, and professional development.
Corporate Social Responsibility Impact
Sanofi India's CSR initiatives have created substantial community impact, particularly in healthcare access and diabetes awareness programs.
CSR Program: Beneficiaries Focus Area Type 1 Diabetes Program: 1,400+ Healthcare support KiDS Program: 1,487,493 Diabetes awareness in schools Mobile Medical Units: 332,000 Non-communicable disease screening
The programs target vulnerable and marginalized communities, with 100% of beneficiaries from these groups across health-focused initiatives. The company's approach emphasizes preventive healthcare, health education, and improving access to quality medical services in underserved areas.
Governance and Compliance Framework
The report demonstrates robust governance structures with dedicated oversight mechanisms for ESG matters. The Managing Director chairs a management-level ESG committee comprising senior leaders from various functions including finance, HR, safety, and communications.
Key governance highlights include updated Code of Conduct aligned with Indian laws and global standards, comprehensive anti-bribery policies, and mechanisms for conflict of interest management. The company maintains zero tolerance for corruption and has implemented whistleblower protection measures.
Stakeholder Engagement and Value Chain
Sanofi India engages with diverse stakeholder groups including patients, healthcare professionals, employees, suppliers, and local communities through structured communication channels. The company assessed 1,611 suppliers for sustainability performance in 2025, with 92% meeting sustainability requirements across areas including health and safety practices, working conditions, and human rights standards.
The sustainability report reflects Sanofi India's integrated approach to business responsibility, combining operational excellence with environmental stewardship and social impact. The comprehensive disclosure demonstrates the company's commitment to transparency and accountability in its ESG journey while supporting India's sustainable development objectives.
